Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Invitation to Orion’s Virtual Capital Markets Day on 26 May 2021
By: GlobenewsWire - 04 May 2021Back to overview list

ORION CORPORATION INVESTOR NEWS 4 MAY 2021 at 9.00 EEST              
        

Invitation to Orions Virtual Capital Markets Day on 26 May 2021

Orion will arrange a virtual Capital Markets Day 2021 for investors, analysts and media on 26 May 2021 at 13:00–16:00 EEST. At the event, Orion's management will provide an update on the company's strategy and targets, business and research & development projects. The presentations are divided into two main themes which are ‘Creating growth towards 2025 target and beyond’ and ‘Creating long-term value’.

Speakers and programme

Main themeSpeaker
Orion’s strategy and introductionTimo Lappalainen, President & CEO
Creating growth towards 2025 target and beyondSatu Ahomäki, SVP, Proprietary Products and Commercial Operations
Niclas Lindstedt, VP, Animal Health
Virve Laitinen, SVP, Specialty Products
Jari Karlson, CFO 
 

Creating long-term value

 
Outi Vaarala, SVP, Research & Development
Liisa Hurme, SVP, Global Operations
ConclusionsTimo Lappalainen, President & CEO

Participants of the Capital Markets Day are kindly asked to register for the event through this link. Participants will have the opportunity to ask questions from Orion’s management during the event.

Contact person:

Tuukka Hirvonen, Investor Relations, Orion Corporation
Tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.


Related companies:Orion Corporation
Copyright 2021 GlobenewsWire Back to overview list
to the top ↑